9/30/2020  8:00:17 AM Chg. -3.18 Volume Bid6:04:53 PM Ask6:04:53 PM Market Capitalization Dividend Y. P/E Ratio
74.33EUR -4.10% 0
Turnover: 0.00
76.79Bid Size: 500 76.99Ask Size: 500 16.75 bill.EUR - -

Business description

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.
 

Management board & Supervisory board

CEO
Hervé Hoppenot
Management board
Christiana Stamoulis, Barry P. Flannelly, Dr. Dashyant Dhanak, Dr. Lothar H. Finke, Dr. Wenqing Yao, Jonathan E. Dickinson, Maria E. Pasquale, Michael Morrissey, Paula J. Swain, Steven H. Stein, M.D., Vijay Iyengar, M.D.
Supervisory board
Hervé Hoppenot, Dr. Jacqualyn A. Fouse, Dr. Wendy Dixon, Edmund P. Harrigan, M.D., Jean-Jacques Bienaimé, Julian C. Baker, Katherine High, M.D., Paul A. Friedman, M.D., Paul J. Clancy
 

Company data

Name: Incyte Corporation
Address: 1801 Augustine Cut-Off,Wilmington, DE 19803, USA
Phone: +1-302-498-6700
Fax: -
E-mail: -
Internet: www.incyte.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 47.80%
IPO date: -

Investor relations

Name: Michael Booth
IR phone: +1-302-498-5914
IR Fax: -
IR e-mail: mbooth@incyte.com

Main Shareholders

Freefloat
 
47.80%
Felix J. Baker
 
15.00%
Baker Bros. Advisors LP
 
14.80%
The Vanguard Group
 
9.20%
BlackRock, Inc.
 
7.00%
Wellington Management Group LLP
 
6.20%